Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.

Martine C MaculaitisXianchen LiuOliver WillMadelyn HansonLynn McRoyAlexandra BerkMelissa Crastnopol

Published in: Patient preference and adherence (2020)

The risks of diarrhea and Grade 3/4 neutropenia were key drivers of both oncologist and patient preferences. Overall, the palbociclib + aromatase inhibitor (AI) profile was most preferred, due to its association with a lower risk of diarrhea and no ECG monitoring, compared with abemaciclib + AI and ribociclib + AI profiles, respectively.

Keyphrases

artificial intelligence
case report
squamous cell carcinoma
irritable bowel syndrome
decision making
small cell lung cancer
clostridium difficile
machine learning
heart rate variability
heart rate
deep learning